NASDAQ · NKTX
Nkarta, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for NKTX: Nov 9, 2026
Nkarta, Inc. Common Stock is estimated to report earnings on 11/09/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 3 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.4. The reported EPS for the same quarter last year was $-0.29.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.40 | $-0.35 | $-0.46 | 3 |
| Dec 2026 | $-0.42 | $-0.35 | $-0.48 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
MarketBeat · RTTNews · Zacks · Fintel- MarketBeat · Sep 27, 3:02 PM EDTNkarta Targets ACR 2026 Data Reveal as Outpatient CAR NK Trials AdvanceNkarta (NASDAQ:NKTX) said it expects to present initial clinical data from its autoimmune disease programs at the American College of Rheumatology’s 2026 Convergence meeting in November, including presentations in myositis, scleroderma and program-wide safety. The company is dev
- RTTNews · Aug 11, 1:57 AM EDTNkarta Posts Wider Loss In Q2; Provides Clinical Update On NKX019(RTTNews) – Nkarta, Inc., (NKTX) a clinical-stage biotech company, posted its second quarter financial results, reflecting a wider net loss compared with the prior-year quarter, primarily attributed to higher operating expenses and lower other income. The company has also provide
- Zacks · Apr 17, 10:28 AM EDTNKTX Stock Up on Upbeat Regulatory Update on Lead Autoimmune ProgramNkarta stock jumps after FDA backs protocol changes for ongoing NKX019 studies, enabling outpatient dosing and boosting study efficiency, patient access and commercial potential.
- Fintel · Nov 11, 7:04 PM ESTStifel Maintains Nkarta (NKTX) Buy RecommendationFintel reports that on November 11, 2025, Stifel maintained coverage of Nkarta (NasdaqGS:NKTX) with a Buy recommendation. Analyst Price Forecast Suggests 527.69% Upside
- The Motley Fool · Aug 13, 4:12 PM EDTNkarta Posts Narrower Loss in Q2Net loss per share (GAAP) of $(0.31) came in ahead of expectations, beating analyst estimates by $0.04 (GAAP).
- Quiver Quantitative · Jul 17, 3:16 PM EDT$NKTX stock is up 12% today. Here's what we see in our data.$NKTX stock has now risen 12% today, according to our price data from Polygon. There has been approximately $2,553,580 of trading volume.
- RTTNews · Jun 6, 9:45 AM EDTNkarta CMO David Shook Steps Down, Shawn Rose To Succeed(RTTNews) – Nkarta, Inc. (NKTX), a clinical-stage biopharmaceutical company, on Friday announced that Chief Medical Officer David Shook will be stepping down and Shawn Rose will take over as CMO and Head of Research and Development, effective June 23.
- Quiver Quantitative · Jun 6, 9:00 AM EDTNkarta, Inc. Appoints Dr. Shawn Rose as Chief Medical Officer and Head of R&DNkarta, Inc. appoints Dr. Shawn Rose as CMO to advance NK cell therapies for autoimmune diseases, succeeding Dr. David Shook.
- Zacks · May 19, 12:00 PM EDTNkarta (NKTX) Moves to Buy: Rationale Behind the UpgradeNkarta (NKTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Quiver Quantitative · May 19, 6:31 AM EDTNew Analyst Forecast: $NKTX Given 'Market Perform' RatingWe just received data on a new analyst forecast for $NKTX. William Blair gave a rating of 'Market Perform' for $NKTX.
- Zacks · Apr 14, 12:00 PM EDTNkarta (NKTX) Upgraded to Buy: Here's WhyNkarta (NKTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Quiver Quantitative · Mar 27, 11:30 AM EDT$NKTX stock is up 53% today. Here's what we see in our data.$NKTX stock has now risen 53% today, according to our price data from Polygon. There has been approximately $35,639,982 of trading volume.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Nkarta, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.